

My name:

My contact number:

Emergency contact:

Emergency contact number:

Name of Haematologist/  
Oncologist/Oncology Nurse:

Contact number:

After-hours contact number:

Name of my Hospital:

My Hospital contact number:

## PATIENT ALERT CARD

### XOSPATA<sup>®</sup>

FILM-COATED TABLETS 40 MG  
(gilteritinib)

- Carry this card with you **at all times**, especially when you travel or when you see another doctor.
- Please ensure you show this card to any doctor, pharmacist or nurse for any medical treatment or at any visits to the hospital or clinic.
- Please contact your doctor **immediately**, if you develop any side effects, in particular those listed on this card.

162912



 **astellas**

## **IMPORTANT SAFETY INFORMATION FOR PATIENTS**

### **Xospata may cause serious side effects, including differentiation syndrome.**

Differentiation syndrome is a condition that affects your blood cells and may be life-threatening or lead to death if not treated in a timely manner.

Talk to your doctor, pharmacist or nurse **immediately** if you have any of the following symptoms:

- Fever
- Trouble Breathing
- Rash
- Dizziness or lightheadedness
- Rapid weight gain
- Swelling of your arms or legs

Differentiation syndrome can happen any time during the first 3 months of treatment from as early as 1 day after starting treatment. Getting medical treatment early may stop the problem from becoming more serious.

Your doctor will monitor you, may pause your treatment and/or may give you a medicine to treat your condition.

If you have any further questions about your treatment, please contact your doctor.

## **IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS**

- This patient is being treated with Xospata (gilteritinib), which can cause differentiation syndrome.
- Symptoms include fever, dyspnoea, pleural effusion, pericardial effusion, pulmonary oedema, hypotension, rapid weight gain, peripheral oedema, rash, and renal dysfunction.
- If differentiation syndrome is suspected, corticosteroid therapy should be initiated along with hemodynamic monitoring until symptom resolution.
- If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, Xospata should be interrupted until signs and symptoms are no longer severe.

Please contact the patient's Haematologist/Oncologist for more information and consult the Product Information for gilteritinib available at <http://eservice.hsa.gov.sg/prism/common/enquirepublic/SearchDRBProduct.do?action=load>

This document has been approved by HSA as of 28-Jan-2021.